v3.26.3
STOCKHOLDERS’ EQUITY (DEFICIT)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY (DEFICIT)

NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

Warrants

 

During the three and nine months ended September 30, 2026 and 2025, the Company did not issue any warrants. As of September 30, 2026 the Company did not have any warrants outstanding. As of December 31, 2025, the Company had 199,733 warrants outstanding at an exercise price of $0.66, which expired unexercised in April 2026.

 

Series B-1 Convertible Preferred Stock (“B-1 Stock”)

 

On June 15, 2023, the Company amended the Articles of Incorporation to authorize 5,000,000 shares of the B-1 Stock (“B-1 shares”). The B-1 shares are convertible into common shares, at a rate of 66.66 of common stock for each share of B-1 shares. The par value of the B-1 shares is $0.0001. The B-1 shares shall not be entitled to any dividends and have no voting rights. In the event of a liquidation, the B-1 Stockholders are entitled to distribution prior to common stockholders but not before any other preferred stockholders.

 

On December 18, 2024, the Company entered into a cancellation agreement with related party promissory note holders for cancellation of $3,665,303 in outstanding principal and interest in exchange for issuance of 750,075 shares of the Company’s B-1 Stock.

 

The Series B-1 Preferred Shares and any shares of common stock issued under the aforementioned agreements are “restricted” securities under Rule 144 of the Securities Act of 1933, as amended.

 

The B-1 shares have a liquidation preference of $1.00 per share or $765,075 as of September 30, 2026 and December 31, 2025, respectively.

 

 

Options

 

In 2005, the Company authorized the 2005 Equity Plan that made available shares of common stock for issuance through awards of options, restricted stock, stock bonuses, stock appreciation rights and restricted stock units. All outstanding stock options expired unexercised on August 5, 2026. The following table summarizes stock option activity for the nine months ended September 30, 2026:

 

   Shares  

Weighted Average Exercise Price

  

Weighted Average Fair Value

  

Weighted Average Remaining Contractual Term (Years)

  

Intrinsic Value

 
Outstanding, January 1, 2026   8,288    1.448    1.62    0.60    — 
Granted   —    —    —    —    — 
Exercised   —    —    —    —    — 
Forfeited/expired   (8,288)   1.448    1.62    —    — 
Outstanding, September 30, 2026   —    —    —    —    — 
                          
Vested/exercisable at September 30, 2026   —    —    —    —    —